Le Lézard
Classified in: Health, Business
Subjects: PER, ACC, CXP, MAT

ECH Announces Intention to Demerge Group of Companies


Independent Management and New Corporate Advisers Will Reinforce Reputation at the Forefront of the Global Cannabis Industry

ECH Media & Data and ECH Medical Will Pursue Two Very Distinct Growth Strategies

LONDON, June 25, 2019 /PRNewswire/ -- ECH (European Cannabis Holdings), the London based group of companies with a fundamental anchor in the global cannabis market, intends to demerge its operating companies and roll out two separate holding companies with a new management team and stand-alone growth strategy for each.

Jeremy Edelman, Chairman, commented: "Our investment and incubation model has proved to be highly successful over the last 18 months. We put this down to a genuine understanding of cannabis and emerging markets, clarity of vision, strong strategic execution and an exceptionally talented team. This industry is now maturing and opening up at pace, so we are proud to announce this demerger which ensures independence and integrity across two distinctly different propositions."

The company has engaged a new advisory team of Strand Hanson, Hill Dickinson and PKF to support and advise on the demerger and associated future transactions.

ECH MEDIA & DATA

This new company will focus on delivering the industry's only truly global offering across data, intelligence, consultancy and networking.

The following brands will form the key pillars of growth:

The company will be headquartered in London, UK, with the tech & data team in Dublin, Ireland and the consultancy & regulatory affairs team in Barcelona, Spain.

Leadership will consist of Jeremy Edelman (Chairman), Stephen Murphy (CEO) and Daragh Anglim (MD, Prohibition Partners). Cannabis Europa and European Cannabis Week are joint ventures.

ECH MEDICAL

A new medical holding company will take a comprehensive approach to improving access to medical cannabis for eligible patients around Europe by providing key infrastructure and educational services.

It will include the following subsidiaries:

Dean Friday, previously ECH's CFO, will take the reigns as CEO and will be joined on the leadership team by Prof. Mike Barnes (Chairman), Hannah Simon (COO), Jonathan Nadler (MD, Academy), Robert Whitehouse (MD, Astral) and Richard North (MD, Clinics). New Country Managers are being recruited at present for key European markets.

Hannah Deacon, the tireless campaigner for UK access to medical cannabis for her young son Alfie Dingley and other children, will be Patient Advocacy Specialist.

The wider medical and scientific team includes Dr David Mc Dowell, Dr Elizabeth Iveson, Dr Dani Gordon, and Dr Leon Barron as well as a number of highly respected specialist physicians in the UK and general practitioners across Europe.

Logo: https://mma.prnewswire.com/media/813128/ECH_Logo.jpg

ECH logo (PRNewsfoto/ECH)

 


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:39
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:35
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...

at 19:14
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...



News published on and distributed by: